Dyadic sells Alphazyme equity interest for ~$1.27M, retains sublicense rights

DYADIC INTERNATIONAL INC

Received approx. $1.27M from sale of Alphazyme equity interest.
Non-exclusive sublicense remains; Dyadic gets milestone/royalty payments on C1-expressed products.
Potential additional payments based on future sales of Alphazyme's existing products.
Alphazyme Sale Agreement executed January 18, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DYADIC INTERNATIONAL INC entered into Alphazyme Sale Agreement with Alphazyme, LLC valued at approximately US$1.27 million (effective 2023-01-18).

Action: entry
Agreement: asset purchase
Counterparty: Alphazyme, LLC
Value: approximately US$1.27 million
Effective: 2023-01-18

Exact text from the filing

On January 18, 2023, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into a Securities Purchase Agreement under which the Company agreed to sell its equity interest in Alphazyme, LLC (the "Alphazyme Sale Agreement").

View on SEC.gov

Browse all material agreements →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-001616

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.